Montelukast

Montelukast, the active ingredient in Montelukast, is a leukotriene receptor antagonist presented as a tablet for oral use. It is indicated for the management of asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in adults and children. GNH USA supplies Montelukast as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is a leukotriene receptor antagonist used to treat conditions mediated by cysteinyl leukotrienes.

Asthma: improves control of chronic asthma and reduces the frequency of exacerbations. Allergic rhinitis: relieves nasal congestion, sneezing and itching associated with seasonal or perennial allergies. Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during or after physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort. - Cough: transient irritation. - Sore throat: mild irritation of the pharynx. - Nausea: occasional upset stomach. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Allergic reactions: angioedema, anaphylaxis, or severe rash. - Mood changes: depression, agitation, or suicidal thoughts. - Hepatic effects: elevated liver enzymes or hepatitis. - Stevens‑Johnson syndrome: severe skin detachment. - Severe rash: drug reaction with eosinophilia and systemic symptoms (DRESS). - Respiratory distress: paradoxical worsening of asthma symptoms.

When prescribing Montelukast, clinicians should consider several safety measures.

Monitor mood: watch for depression, anxiety, or suicidal ideation. Assess liver function: consider baseline and periodic liver enzyme testing. Review asthma control: ensure patients have an appropriate rescue inhaler. Avoid in hypersensitivity: do not use in patients with known allergy to Montelukast or excipients. Pregnancy and lactation: safety data are limited; use only if benefit outweighs risk. Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines that affect its metabolism or pharmacodynamic profile.

Major Interactions (Avoid): - Ritonavir (strong CYP3A4 inhibitor): may increase Montelukast plasma levels. - Phenobarbital (enzyme inducer): may reduce therapeutic effect.

Moderate Interactions (Monitor Closely): - Fluconazole (moderate CYP3A4 inhibitor): may modestly raise levels. - Erythromycin (CYP3A4 inhibitor): potential increase in exposure. - Carbamazepine (enzyme inducer): may lower effectiveness. - Warfarin: monitor INR as Montelukast can occasionally affect anticoagulation.